|
|
| |
| Almost four decades of experience since its inception in 1966, have taken the CIRON Group from strength to strength in the health care business. The small company started by Mr. R.T. Shah has grown into large and dynamic Group which currently occupies a leading position in the fields of pharmaceutical formulations manufacturing and export. |
|
|
|
|
| |
|
|
| |
Headquartered in Mumbai, India, with manufacturing units in Tarapur, CIRON Group has built up a reputation for excellence on the foundations of consistently high quality, a constantly expanding product portfolio, timely deliveries and state-of-the-art manufacturing facilities, conforming to the most demanding international standards. |
|
| |
|
|
| |
 |
This unflagging commitment to quality and customer satisfaction has won the group a high penetration rate in the domestic market and has also carved a significant global niche for its products. Today Ciron boasts an overseas presence in over 36 countries. |
|
|
| |
|
|
| |
Since its establishment CIRON is amongst a leading manufacturer and exporter of pharmaceutical formulations such as tablets, capsules, syrups, injections, ointments and powders. Since then with its own efforts & backing by its directors who themselves are pharmacy graduates, expanded its product range & improved on quality thereby making it market friendly in India & abroad. |
|
| |
|
|
| |
Besides the generic formulations, a number of products in its own brand name are also produced and exported. In our endeavor to make available the best quality of medicines to alleviate the sufferings of mankind, we offer products of international standards & keep strict control over quality at every stage. |
|
| |
|
|
| |
|
Foreseeing that survival in 90’s depend on being able to manufacture products as good as those available in the world, CIRON in 2001 renovated its plant and adopted GMP. CIRON invests almost 40% of its annual profits in latest plant and machinery and training of technical personnel ensuring continuous up gradation of quality of its products in line with world class technology.
|
 |
|
|
| |
|
|
| |
CIRON set a goal of introducing a range of specialized products based on leading technologies available globally. CIRON to day exports its products to United States of America, the United Kingdom, France, Belgium, Germany, Switzerland, Denmark, Russia, the Netherlands, the Philippines, Nigeria, Ghana, Niger, Sudan, Kenya, Zaire, Benin, Mali, Cameroon, Vietnam, Costa Rica, Djibouti, the Dominican Republic, Panama, Papua New Guinea, Yemen and Vietnam & others. |
|
| |
|
|
| |
The congenial environment; well built infrastructure; energetic & highly competent technical staff and workforce; unique human relationship; efficient & committed management support in practicing up-to-date Quality Management Systems; resulted in meeting highest quality standards, safety and productivity. |
|
| |
|
|
| |
Currently,
the CIRON Group comprises the flagship company Ciron
Drugs & Pharmaceuticals Pvt. Ltd., as well Oboi
Laboratories. The CIRON team, headed by able and experienced
managers, comprises over 50 well-qualified technical
personnel and 200 workmen - all dedicated to delivering
the highest possible levels of customer satisfaction. |
|
| |
|
|
| |
|
The CIRON Group's strong manufacturing
competence, its committed team and its continuous
pursuit of total quality are all focussed on further
expanding CIRONS large base of satisfied clients
and fulfilling its objective of becoming a world
leader in formulations for the pharmaceutical
industry.
|
 |
|
|
| |
|
|
| |
The
formulation (drug in a ready-to-consume
form such as tablet) in the generic market
is referred to as Abbreviated New Drug
Application (ANDA). It is called ANDA
because the generic manufacturer does
not have to go through the elaborate clinical
trials that the original patent-holder
would have to go through. Since the properties
of the drug are already known, the trials
for generics are limited when compared
to a new drug.
The
US regulatory authority looks at aspects
such as bioequivalence (the rate at which
the drug is absorbed in the bloodstream)
when granting approval to a generic formulation.
This is to make sure that the generic
drug performs with the same effectiveness
as the branded drug in the human body.
ANDA approvals are not an easy affair.
The costs and delays are a factor to reckon
with. As in the case of the bulk drugs,
the manufacturing facilities have to be
approved by the US regulatory authorities. |
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
Ciron
Inc |
|
| |
Copyrights
Ciron Drugs & Pharmaceuticals Pvt. Ltd. All Rights
Reserved.
Designed by: Ambest
Media |
|
|
|
|
